Myasthenia gravis: Subgroup classification and therapeutic strategies

The Lancet Neurology

Volumn 14, Issue 10, 2015, Pages 1023-1036

  Gilhus, Nils Erik ^a,b   Verschuuren, Jan J ^c  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LIPOPROTEIN RELATED PROTEIN 4; MEMBRANE PROTEIN; METHOTREXATE; MUSK PROTEIN; MYCOPHENOLATE MOFETIL; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY BLOOD LEVEL; BULBAR PARALYSIS; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; DISEASE CLASSIFICATION; HEART CONDUCTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOSITIS; PHYSICAL ACTIVITY; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THYMECTOMY; THYMOMA; THYMUS HYPERPLASIA; TREATMENT RESPONSE; CLASSIFICATION; IMMUNOLOGY;

HUMANS; MYASTHENIA GRAVIS;

EID: 84942436213     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00145-3     Document Type: Review

References (112)

1. Meriggioli MN, Sanders DB Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009, 8:475-499.
2. Gilhus NE Myasthenia and neuromuscular junction. Curr Opin Neurol 2012, 25:523-529.
3. Querol L, Illa I Myasthenia and the neuromuscular junction. Curr Opin Neurol 2013, 26:459-465.
4. Verschuuren JJ, Huijbers MG, Plomp JJ, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013, 12:918-923.
5. Zisimopoulou P, Brenner T, Trakas N, Tzartos SJ Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013, 12:924-930.
6. Owe JF, Daltveit AK, Gilhus NE Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J Neurol Neurosurg Psychiatry 2006, 77:203-207.
7. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010, 17:893-902.
8. Suh J, Goldstein JM, Nowak RJ Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 2013, 86:255-260.
9. Jacob S, Viega S, Leite MI Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 2012, 69:994-1001.
10. Yang L, Maxwell S, Leite MI, et al. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. J Neurol Sci 2011, 301:71-76.
11. Cole RN, Ghazanfari N, Ngo ST, et al. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to dissembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 2010, 17:3217-3229.
12. Y, Ito M, Hirayama M, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011, 77:1819-1828.
13. Plomp JJ, Huijbers MG, Maarel SMVD, Verschuuren JJ Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis. Ann NY Acad Sci 2012, 1275:114-122.
14. Shen C, Lu Y, Zhang B, et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 2013, 123:5190-5202.
15. Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology 2014, 82:1976-1983.
16. Zhang B, Shen C, Bealmear B, et al. Autoantibodies to agrin in myasthenia gravis. PLoS One 2014, 9:e91816.
17. Gallardo E, Martinez-Hernandez E, Titulaer MJ, et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev 2014, 13:1003-1007.
18. Skeie GO, Mygland A, Treves S Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro. Muscle Nerve 2003, 27:81-89.
19. Romi F, Aarli JA, Gilhus NE Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 2007, 14:617-620.
20. Heldal AT, Owe JF, Gilhus NE, et al. Seropositive myasthenia gravis; a nationwide epidemiologic study. Neurology 2009, 73:150-151.
21. Andersen JB, Engeland A, Owe JF, et al. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010, 17:1445-1450.
22. Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010, 10:46.
23. Pakzad Z, Aziz T, Oger J Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 2011, 76:1526-1528.
24. Pedersen EG, Hallas J, Hansen K, et al. Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009. Eur J Neurol 2012, 20:942-948.
25. VanderPluym J, Vajsar J, Jacob FD, et al. Clinical characteristics of pediatric myasthenia: a surveillance study. Pediatrics 2013, 132:e939-e944.
26. Niks EH, Kuks JBM, Verschuuren JJGM Epidemiology of myasthenia gravis witht anti-muscle specific kinaase antibodies in the Netherlands. J Neurol Neurosurg Psychiatry 2007, 78:417-418.
27. Guptill JT, Sanders DB, Evoli A Anti-MuSK antibody myasthenia gravis; clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011, 44:36-40.
28. Rodolico C, Toscano A, Autunno M, et al. Limb-girdle myasthenia; clinical, electrophysiological and morphological features in familial and autoimmune cases. Neuromuscul Disord 2002, 12:964-969.
29. Gilhus NE, Nacu A, Andersesn JB, Owe JF Myasthenia gravis and risks for comorbidity. Eur J Neurol 2015, 22:17-23.
30. Liewluck T Immune-mediated rippling muscle disease; another inflammatory myopathy in myasthenia gravis. Arch Neurol 2010, 67:896-897.
31. Mehanna R, Patton EL, Phan CL, Harati Y Amyotrophic lateral sclerosis with positive anti-acetylcholine receptor antibodies; case report and review of the literature. J Clin Neuromuscul Dis 2012, 14:82-85.
32. Filosso PL, Galassi C, Ruffini E, et al. Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study. Eur J Cardiothor Surg 2013, 44:219-224.
33. Pedersen EG, Pottegard A, Hallas J, et al. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur J Neurol 2013, 20:942-948.
34. Pedersen EG, Pottegard A, Hallas J, et al. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. Eur J Neurol 2014, 20:942-948.
35. Owe JF, Davidsen ES, Eide GE, et al. Left ventricular long-axis function in myasthenia gravis. J Neurol 2008, 255:1777-1784.
36. Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 2009, 66:1334-1338.
37. Kumagai S, Kato T, Ozaki A, et al. Serial measurements of cardiac troponin I in patients with myasthenia gravis-related cardiomyopathy. Int J Cardiol 2013, 168:e79-e80.
38. Suzuki S, Utsugisawa K, Suzuki N Overlooked non-motor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry 2013, 84:989-994.
39. Alkhawajah NM, Oger J Late-onset myasthenia gravis; a review when incidence in older adults keeps increasing. Muscle Nerve 2013, 48:705-710.
40. Maniaol AH Lee AT, et al. Risk for myasthenia gravis maps to a (151) pro-ala change in TNIP1 and human leukocyte antigen-B 08. Ann Neurol 2012, 72:927-935.
41. Renton AE, Piner HA, Provenzano C, et al. A genome-wide association study of myasthenia gravis. JAMA Neurol 2015, 72:396-404.
42. Klein R, Marx A, Ströbel P, et al. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum Immunol 2013, 74:1184-1193.
43. Maniaol AH, Elsais A, Lorentzen ÅR, et al. Late onset myasthenia gravis is associated with HLA DRB115:01 in the Norwegian population. PLoS One 2012, 7:e36603.
44. Marx A, Pfister P, Schalke B, et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12:875-884.
45. Skjei KL, Lennon VA, Kuntz NL Muscle specific kinase autoimmune myasthenia gravis in children: a case series. Neuromuscul Disord 2013, 23:874-882.
46. Bartoccioni E, Scuderi F, Augugiaro A, et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009, 72:195-197.
47. Klooster R, Plomp JJ, Huijbers MG, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012, 135:1081-1101.
48. Alahgholi-Hajibehzad M, Yilmaz V, Guisen-Parman Y, et al. Association of HLA-DR13114,-DR13116 and -DQB105 with MuSK-myasthenia gravis in patients from Turkey. Hum Immunol 2013, 74:1633-1635.
49. Higuchi O, Hamuo J, Motomura M, et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
50. Zhang B, Tzartos JS, Viegas S, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-negative myasthenia gravis. Arch Neurol 2012, 69:445-451.
51. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in "seronegative" myasthenia gravis. Brain 2008, 131:1940-1952.
52. Cossins J, Belaya K, Zoltowska K, et al. The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 2013, 1275:123-128.
53. Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE EFNS/ENS guidelines for the treatment of ocular myasthenia gravis. Eur J Neurol 2014, 21:687-693.
54. Romi F, Bo L, Skeie GO, et al. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol 2002, 128:82-89.
55. Cufi P, Dragin N, Weiss JM, et al. Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis. Ann Neurol 2012, 73:281-293.
56. Panse RL, Berrih-Aknin S Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation. Curr Opin Neurol 2013, 26:569-576.
57. Mehndiratta MM, Pandey S, Kuntzer T Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev 2014, CD006986.
58. Mount FW Corticotropin in treatment of ocular myasthenia; a controlled clinical trial. Arch Neurol 1964, 11:114-124.
59. Howard FM, Duane DD, Lambert EH, Daube JR Alternate-day prednisone: preliminary report of a double-blind controlled study. Ann N Y Acad Sci 1976, 274:596-607.
60. Lindberg C1, Andersen O, Lefvert AK Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 1998, 97:370-373.
61. Benatar M, McDermott MP, Sanders DB, et al. Efficacy of Prednisone for the Treatment of Ocular Myasthenia (EPITOME): a randomized controlled trial. Muscle Nerve 2015, for the Muscle Study Group (MSG), published online July 14. 10.1002/mus.24769.
62. Bromberg MB, Wald JJ, Forshew DA, et al. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci 1997, 150:59-62.
63. Palace J, Newsom-Davis J, Lecky B A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998, 50:1778-1783.
64. Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987, 316:719-724.
65. Tindall RS, Philips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993, 681:539-551.
66. Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of myasthenia gravis; a randomized pilot study. Eur Neurol 2005, 53:146-150.
67. Yoshikawa H, Kiuchi T, Saida T, et al. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011, 82:970-977.
68. Meriggioli MN, Rowin J, Richman JG, Leurgans S Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 2003, 998:494-499.
69. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008, 71:400-406.
70. Pasnoor M, He J, Herbelin L, et al. Phase II trial of methotrexate in myasthenia gravis. Ann N Y Acad Sci 2013, 1275:23-28.
71. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997, 41:789-796.
72. Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002, 26:549-552. for the Myasthenia Gravis-IVIG Study Group.
73. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 2005, 62:1689-1693. for the Myasthenia Gravis Clinical Study Group.
74. Zinman L, Ng E, Bril V IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007, 68:837-841.
75. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011, 76:2017-2023.
76. Howard JF, Barohn PJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013, 48:76-84.
77. Sanders DB, Rosenfeld J, Dimachkie MM, et al. A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety and tolerability of single doses of tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis. Neurotherapeutics 2015, 12:455-460.
78. Hart IK, Sthasiam S, Sharshar T Immunosuppressive agents for myasthenia gravis (review). Cochrane Database Syst Rev 2007, CD005224.
79. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Ann Thorac Surg 2000, 70:327-334.
80. Benatar M, Sanders DB, Wolfe GI, McDermott MP, Tawil R Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann N Y Acad Sci 2012, 1275:17-22.
81. Benveniste O, Hilton-Jones D The role of rituximab in the treatment of myasthenia gravis. Eur Neurol Rev 2010, 5:95-100.
82. Benatar M, Kaminski H Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev 2012, CD005081.
83. Pouwels S, Boer AD, Javaid MK, et al. Fracture rates in patients with myasthenia gravis; the general practice research database. Osteoporos Int 2013, 24:467-476.
84. Marinkovic G, Kroon J, Hoogenboezem M, et al. Inhibition of GTPase rac1 in endothelium by 6-mercaptpurine results in immunosuppression in nonimmune cells; new target for an old drug. J Immunol 2014, 192:4370-4378.
85. Norwood F, Dhanjal M, Hill M, et al. Myasthenia in pregnancy; best practice guidelines from a UK multispeciality working group. J Neurol Neurosurg Psychiatry 2014, 85:538-543.
86. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008, 71:394-399. The Muscle Study Group.
87. Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis; outcomes in 102 patients. Muscle Nerve 2010, 41:593-598.
88. Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011, 82:659-663.
89. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011, 82:671-673.
90. Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment of rituximab in MuSK myasthenia. Neurology 2012, 78:189-193.
91. Keung B, Robeson KR, DiCapua DB, et al. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry 2013, 84:1407-1409.
92. Yi JS, DeCroos EC, Sanders DB, et al. Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle Nerve 2013, 48:992-993.
93. Heckmann JM, Rawoot A, Bateman K, et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 2011, 11:97.
94. Benatar M, Sanders D The importance of studying history; lessons learnt from a trial of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011, 82:945.
95. Gronseth GH, Barohn RJ Thymectomy for autoimmune myasthenia gravis (an evidence-based review). Neurology 2000, 55:7-15.
96. Cea G, Benatar M, Verdugo RJ, Salinas RA Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database Syst Rev 2013, cd008111.
97. Ye B, Tantal J-C, Li W, et al. Video-assisted thoracoscopic surgery versus robotic-assisted thoracoscopic surgery in the surgical treatment of Masaoka stage I thymoma. World J Surg Oncol 2013, 11:157-162.
98. Liew WKM, Kang PB Update on juvenile myasthenia gravis. Curr Opin Pediatr 2013, 25:694-700.
99. Gajdos P, Chevret S, Toyka KV Plasma exchange for generalised myasthenia gravis. Cochrane Database Syst Rev 2002, CD002275.
100. Mandawat A, Kaminski H, Cutter G, et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 2010, 68:797-805.
101. Barth D, Nabavi N, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011, 76:2017-2023.
102. Gilhus NE Acute treatment for myasthenia gravis. Nat Rev Neurol 2011, 7:132-134.
103. Gajdos P, Chevret S, Toyka KV Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012, CD002277.
104. Ferrero S, Pretta S, Nicoletti A, et al. Myasthenia gravis: management issues during pregnancy. Eur J Obst Gynecol Reproduct Biol 2005, 121:129-138.
105. Hoff JM, Daltveit AK, Gilhus NE Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007, 14:38-43.
106. Hoff JM, Loane M, Gilhus NE, et al. Arthrogryposis multiplex congenital: an epidemiologic study of nearly 9 million births in 24 Eurocat registers. Eur J Obst Gynecol Reproduct Biol 2011, 159:347-350.
107. Ragheb S, Lisak R, Lewis R, et al. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol 2008, 65:1358-1362.
108. Gomez AM, Vrolix K, Martinez-Martinez P, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 2011, 186:2503-2513.
109. Rowin J, Thiruppathi M, Arrebamen E, et al. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis; effects on regulatory T cells. Muscle Nerve 2012, 46:449-453.
110. Fee DB, Kasarskis EJ Myasthenia gravis associated with etanercept therapy. Muscle Nerve 2009, 39:866-870.
111. Russell AJ, Hartman JJ, Hinken AC, et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med 2012, 18:452-456.
112. Steinman L The road not taken: antigen-specific therapy and neuroinflammatory disease. JAMA Neurol 2013, 70:1100-1101.